A prospective, multicenter study to evaluate the effect of Fixed dose combination of Tafluprost/timolol in patients with Ocular-hypertension and Open-angle-glaucoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jul 2022 Results of a country level sub-analysis published in the Current Medical Research and Opinion
07 May 2022 Results of a sub-analysis assessed the preservative-free fixed-dose combination of Tafluprost/timolol according to the baseline monotherapy.published in the Advances in Therapy
01 Apr 2022 Results (n=92) from study population in Spain assessing efficacy, safety and tolerability of Tafluprost/Timolol published in the Journal of Ocular Pharmacology and Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com